TCBPY

TC Biopharm (Holdings) Plc

TCBPY, USA

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

https://tcbiopharm.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TCBPY
stock
TCBPY

TC BioPharm Limited Enters Administration Amid Asset Sale Exploration TipRanks

Read more →
TCBPY
stock
TCBPY

TC BioPharm to be delisted from Nasdaq, moves to OTC Markets Investing.com

Read more →

Finn Analysis

(Last Updated 2024-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.17

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-99.12 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-28.91 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

2.43

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of TC Biopharm (Holdings) Plc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-03-31

EPS Actual

-40.36

EPS Estimate

0

EPS Difference

-40.36

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-06-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Moderately Defensive(4.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.3)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(1.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2024-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.